{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:26:25Z","timestamp":1787894785138,"version":"build-2784847793"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of Health National Institute of Neurological Disorders and Stroke","award":["NS51667"],"award-info":[{"award-number":["NS51667"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.neuropharm.2014.11.024","type":"journal-article","created":{"date-parts":[[2014,12,6]],"date-time":"2014-12-06T01:04:53Z","timestamp":1417827893000},"page":"100-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy"],"prefix":"10.1016","volume":"95","author":[{"given":"Farinaz","family":"Nasirinezhad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislava","family":"Jergova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Sagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2014.11.024_bib1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/01.wnl.0000253187.66183.9c","article-title":"Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial","volume":"68","author":"Abrams","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1021\/cr0782067","article-title":"Enzymatic pathways that regulate endocannabinoid signaling in the nervous system","volume":"108","author":"Ahn","year":"2008","journal-title":"Chem. Rev."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.chembiol.2009.02.013","article-title":"Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain","volume":"16","author":"Ahn","year":"2009","journal-title":"Chem. Biol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1124\/jpet.111.180257","article-title":"Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain","volume":"338","author":"Ahn","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.brainresrev.2008.12.003","article-title":"Targeting CB2 receptors and the endocannabinoid system for the treatment of pain","volume":"60","author":"Anand","year":"2009","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib6","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/j.1460-9568.2006.04684.x","article-title":"CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms","volume":"23","author":"Beltramo","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib7","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.chembiol.2007.11.006","article-title":"A\u00a0comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol","volume":"14","author":"Blankman","year":"2007","journal-title":"Chem. Biol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib8","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/j.1476-5381.2011.01445.x","article-title":"The FAAH inhibitor PF-3845 acts in the nervous system to reverse lipopolysaccharide-induced tactile allodynia in mice","volume":"165","author":"Booker","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib9","article-title":"Palmitoylethanolamide, a naturally-occurring lipid, is an orally effective intestinal anti-inflammatory agent","author":"Borrelli","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2091-10-14","article-title":"the endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways","volume":"10","author":"Bradshaw","year":"2009","journal-title":"BMC Biochem."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/sj.bjp.0704110","article-title":"The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain","volume":"133","author":"Bridges","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/sj.bjp.0706699","article-title":"Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms","volume":"148","author":"Chang","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/nn.2632","article-title":"Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism","volume":"13","author":"Clapper","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib15","doi-asserted-by":"crossref","first-page":"9371","DOI":"10.1073\/pnas.161191698","article-title":"Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase","volume":"98","author":"Cravatt","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/384083a0","article-title":"Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides","volume":"384","author":"Cravatt","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1367-5931(03)00079-6","article-title":"Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system","volume":"7","author":"Cravatt","year":"2003","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib18","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archneurol.2010.76","article-title":"Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study","volume":"67","author":"Ellis","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/npp.2008.120","article-title":"Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial","volume":"34","author":"Ellis","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pain.2005.09.005","article-title":"Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat","volume":"118","author":"Elmes","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib21","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/npp.2010.44","article-title":"FAAH_\/_ mice display differential tolerance, dependence, and cannabinoid receptor adaptation after \u03b49-tetrahydrocannabinol and anandamide administration","volume":"35","author":"Falenski","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1124\/jpet.104.078980","article-title":"Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation","volume":"313","author":"Fegley","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3959(00)00474-7","article-title":"The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain","volume":"92","author":"Fox","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.pain.2013.10.023","article-title":"Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs","volume":"155","author":"Freeman","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","article-title":"Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations","volume":"232","author":"Galiegue","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1089\/aid.2011.0116","article-title":"Epidemiology of HIV-related neuropathy \u2013 a systematic literature review","volume":"28","author":"Ghosh","year":"2012","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.phrs.2012.10.013","volume":"67","author":"Guindon","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib28","first-page":"1260","article-title":"A\u00a0placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies","volume":"251","author":"Hahn","year":"2004","journal-title":"J.\u00a0Neurol."},{"issue":"5","key":"10.1016\/j.neuropharm.2014.11.024_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096396","article-title":"Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack analgesic efficacy in rats with neuropathic spinal cord injury pain","volume":"9","author":"Hama","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.expneurol.2006.09.002","article-title":"Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury","volume":"204","author":"Hama","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.brainres.2007.09.013","article-title":"Behavioral characterization and effect of clinical drugs in a rat model of pain following spinal cord compression","volume":"1185","author":"Hama","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brainres.2011.07.031","article-title":"Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain","volume":"1412","author":"Hama","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0165-5728(01)00288-0","article-title":"Peripheral nerve exposure to HIV viral envelope protein gp120 induces neuropathic pain and spinal gliosis","volume":"116","author":"Herzberg","year":"2001","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3940(96)13308-5","article-title":"The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain","volume":"221","author":"Herzberg","year":"1997","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pain.2005.07.007","article-title":"A\u00a0cannabinoid pharmacotherapy for chemotherapy-evoked painful peripheral neuropathy","volume":"118","author":"Hohmann","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib36","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1476-5381.2010.01046.x","article-title":"Central and peripheral sites of action for CB receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats","volume":"162","author":"Hsieh","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib37","doi-asserted-by":"crossref","first-page":"10529","DOI":"10.1073\/pnas.1834309100","article-title":"Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS","volume":"100","author":"Ibrahim","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.bjp.0706510","article-title":"Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models","volume":"147","author":"Jayamanne","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib39","doi-asserted-by":"crossref","first-page":"13318","DOI":"10.1523\/JNEUROSCI.3326-06.2006","article-title":"Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain","volume":"26","author":"Jhaveri","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib40","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.biopsych.2008.08.008","article-title":"Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates","volume":"64","author":"Justinova","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ana.10645","article-title":"Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons","volume":"54","author":"Keswani","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib42","first-page":"1420","article-title":"Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms","volume":"11","author":"Kinsey","year":"2010","journal-title":"J.\u00a0Pain"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib43","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1124\/jpet.109.155465","article-title":"Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain","volume":"330","author":"Kinsey","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib44","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1021\/jm058183t","article-title":"The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications","volume":"48","author":"Lambert","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.283.5400.401","article-title":"Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice","volume":"283","author":"Ledent","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0304-3959(98)00263-2","article-title":"The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats","volume":"81","author":"Li","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib47","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/0006-8993(93)91334-O","article-title":"Antinociceptive actions of cannabinoids following intraventricular administration in rats","volume":"629","author":"Martin","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib48","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0304-3959(99)00045-7","article-title":"Spinal cannabinoids are anti-allodynic in rats with persistent inflammation","volume":"82","author":"Martin","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0091-3057(81)90352-X","article-title":"Use of programmable protocol timer and data logger in the monitoring of animal behavior","volume":"15","author":"Murray","year":"1981","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib50","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/jpet.109.164806","article-title":"Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase","volume":"334","author":"Naidu","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib51","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1476-5381.2012.02028.x","article-title":"Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system","volume":"167","author":"Okine","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib52","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0301-0082(00)00031-9","article-title":"Cannabinoid receptors and pain","volume":"63","author":"Pertwee","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib53","doi-asserted-by":"crossref","first-page":"e14433","DOI":"10.1371\/journal.pone.0014433","article-title":"Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials","volume":"5","author":"Phillips","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib54","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00000542-200310000-00031","article-title":"Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors","volume":"99","author":"Quartilho","year":"2003","journal-title":"Anesthesiology"},{"issue":"195","key":"10.1016\/j.neuropharm.2014.11.024_bib55","first-page":"1","article-title":"Novel endogenous N-acyl amides activate TRPV1-4 receptors, BV-2 microglia, and are regulated in brain in an acute model of inflammation","volume":"8","author":"Raboune","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib56","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.nurt.2009.08.002","article-title":"Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside","volume":"6","author":"Rahn","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib57","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s13365-011-0044-3","article-title":"multinational study of neurological performance in antiretroviral therapy-naive HIV-1-infected persons in diverse resource-constrained settings","volume":"17","author":"Robertson","year":"2011","journal-title":"J.\u00a0Neurovirol."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib58","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.pain.2010.08.045","article-title":"Association of self-reported painful symptoms with clinical and neurophysiologic signs in HIV-associated sensory neuropathy","volume":"151","author":"Robinson-Papp","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib59","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1124\/jpet.107.119941","article-title":"The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3\u2032-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice","volume":"322","author":"Russo","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib60","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/j.1460-9568.2010.07162.x","article-title":"Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain","volume":"31","author":"Sagar","year":"2010","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib61","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1124\/jpet.114.212753","article-title":"Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor\u2013mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice","volume":"350","author":"Schlosburg","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib62","first-page":"243","article-title":"HIV-related neuropathy: current perspectives","volume":"5","author":"Sch\u00fctz","year":"2013","journal-title":"HIV\/AIDS Res. Palliat. Care"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib63","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pain.2004.01.020","article-title":"Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat","volume":"109","author":"Scott","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1212\/WNL.0b013e3181ccc6ef","article-title":"HIV Neuropathy Study Group. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial","volume":"74","author":"Simpson","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib65","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.pain.2014.05.027","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy","volume":"155","author":"Simpson","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neulet.2004.08.061","article-title":"The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats","volume":"371","author":"Ulugol","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00023210-200519040-00005","article-title":"HIV-associated neuropathic pain: epidemiology, pathophysiology and management","volume":"19","author":"Verma","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib68","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pain.2007.02.015","article-title":"Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy","volume":"133","author":"Wallace","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib69","first-page":"2688","article-title":"Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain","volume":"130","author":"Wallace","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib70","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2174\/092986707780363023","article-title":"The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists","volume":"14","author":"Whiteside","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2014.11.024_bib71","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neuroscience.2005.06.009","article-title":"Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons","volume":"135","author":"Wotherspoon","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.11.024_bib72","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1073\/pnas.96.10.5780","article-title":"Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice","volume":"96","author":"Zimmer","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814004407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814004407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T01:49:30Z","timestamp":1566092970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390814004407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":72,"alternative-id":["S0028390814004407"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.11.024","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}